Marinus Pharmaceuticals Inc (MRNS)

(10% Negative) Marinus Pharmaceuticals, Inc. (MRNS) Announces Delay in proposal Trials for a potential interim analysis Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment